AXIS Capital Holdings Limited, through its subsidiaries, provides various specialty insurance and reinsurance products in Bermuda, the United States, and internationally. It operates through two segments, Insurance and Reinsurance. The Insurance segment offers professional insurance products that cover directors' and officers' liability, errors and omissions, employment practices, fiduciary, crime, professional indemnity, medical malpractice, and other financial insurance related coverages for commercial enterprises, financial institutions, not-for-profit organizations, and other professional service providers; and property insurance products for commercial buildings, residential premises, construction projects, property in transit, onshore renewable energy installations, and physical damage and business interruption following an act of terrorism. This segment also provides marine and aviation insurance services for offshore energy, offshore renewable energy, cargo, liability, including kidnap and ransom, fine art, specie, and hull war, hull and liability, and specific war coverage for passenger airlines, cargo operations, general aviation operations, airports, aviation authorities, security firms, and  product manufacturers; personal accident, travel insurance, specialty health products for employer and affinity groups, and pet insurance products; and liability, cyber, and credit and political risk insurance services. The Reinsurance segment offers agriculture, marine and aviation, catastrophe, accidental and health, credit and surety, motor, professional, travel, life, engineering, property, and liability reinsurance products. AXIS Capital Holdings Limited was founded in 2001 and is headquartered in Pembroke, Bermuda.

Axis Capital Holdings Limited

Axis Capital Holdings (($AXS)) has held its Q4 earnings call. Read on for the main highlights of the call. Axis Capital Earnings Call Highlights Re...

Axis Capital Delivers Record Results, Stays Disciplined

Axis Capital ( ($AXS) ) just unveiled an update. On January 27, 2026, AXIS Capital’s board-level Human Capital and Compensation Committee granted a...

Axis Capital Grants Special Equity Award to CEO

Wells Fargo analyst Elyse Greenspan maintained a Buy rating on Axis Capital today and set a price target of $121.00. According to TipRanks, Greensp...

Wells Fargo Sticks to Their Buy Rating for Axis Capital (AXS)

NAXS AB ( ($SE:NAXS) ) has provided an announcement. NAXS AB reported a reduced full-year loss for 2025, with net profit improving to a negative MS...

NAXS Narrows 2025 Loss as New Owners and Board Pivot Strategy Toward Shareholder Value

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Hinge Health, Inc. Class A (HNGE – Research Report), Axsome Thera...

Analysts Conflicted on These Healthcare Names: Hinge Health, Inc. Class A (HNGE), Axsome Therapeutics (AXSM) and TG Therapeutics (TGTX)

NAXS AB ( ($SE:NAXS) ) has shared an update. NAXS AB has repurchased 5,827 of its own shares on Nasdaq Stockholm between 12 and 16 January 2026 as ...

NAXS Steps Up Share Buybacks to Bolster Capital Structure and Shareholder Value

In a report released yesterday, Rowland Mayor from RBC Capital maintained a Buy rating on Axis Capital, with a price target of $125.00. According t...

RBC Capital Reaffirms Their Buy Rating on Axis Capital (AXS)

In a report released today, Graig Suvannavejh from Mizuho Securities reiterated a Buy rating on Axsome Therapeutics, with a price target of $217.00...

Mizuho Securities Keeps Their Buy Rating on Axsome Therapeutics (AXSM)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Axsome Therapeutics (AXSM – Research Report), Vert...

Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), Vertex Pharmaceuticals (VRTX) and CareDx (CDNA)

Axsome Therapeutics ( ($AXSM) ) has provided an announcement. On January 12, 2026, Axsome Therapeutics reported preliminary, unaudited net product ...

Axsome Therapeutics Reports Strong Preliminary 2025 Revenue Growth

NAXS AB ( ($SE:NAXS) ) just unveiled an announcement. NAXS AB has repurchased 4,723 of its own shares on Nasdaq Stockholm between 29 December 2025 ...

NAXS Expands Share Buyback, Lifts Treasury Stake to 48,668 Shares

In a report released today, Ashwani Verma from UBS maintained a Buy rating on Axsome Therapeutics, with a price target of $248.00. According to Tip...

UBS Sticks to Their Buy Rating for Axsome Therapeutics (AXSM)

NAXS AB ( ($SE:NAXS) ) just unveiled an update. NAXS AB has continued to execute its previously announced share repurchase program, buying back 4,7...

Current Quarter	$3.04	Next Quarter	$3.05
Current Year	$12.55	Next Year	$13.53
QoQ Growth	+0.3%	YoY Growth	+7.8%
3Y EPS CAGR	N/A	Target Price	$121.91
Consensus	Buy	Upside	+17.4%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	AXS	$103.86	+0.66%	831.61K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	AXS	$103.86	+0.7%	831.61K
3
4
5
6

AXS

AXS

EPS Estimates Overview

Quarterly EPS Estimates

Revenue Analysis

Get Axis Capital Holdings Limited Data in Excel

Get Axis Capital Holdings Limited Data in Excel